<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03885947</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 14-0451</org_study_id>
    <nct_id>NCT03885947</nct_id>
  </id_info>
  <brief_title>VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies</brief_title>
  <official_title>Phase I Study of Valproic Acid Expanded Cord Blood Stem Cells as an Allogeneic Donor Source for Adults With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alla Keyzner</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this Phase I study, the study team will evaluate the safety of Valproic Acid (VPA)&#xD;
      expanded cord blood stem cells defined by the lack of serious infusion reactions or graft&#xD;
      failure in patients with hematological malignancies undergoing umbilical cord blood&#xD;
      transplantation. Moreover, the study team will also evaluate time to neutrophil and platelet&#xD;
      engraftment as well as transplant related outcomes such as graft versus host disease (GVHD),&#xD;
      treatment related mortality (TRM), and overall survival (OS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I trial for safety of VPA expanded cord blood stem cells in patients with&#xD;
      hematological malignancies undergoing allogeneic stem cell transplantation. The primary&#xD;
      endpoint of the study is safety as defined by the incidence of infusion reactions and graft&#xD;
      failure, lack of neutrophil engraftment by day +42. The trial will consist of two cohorts.&#xD;
      First cohort of 5-7 patients, will undergo double umbilical cord blood (UCB) transplantation.&#xD;
      One UCB unit will undergo CD34 selection followed VPA based expansion. CD34 negative portion&#xD;
      of that unit will be cryopreserved to be infused later following infusion of the expanded&#xD;
      portion. Infusion of the second unmanipulated UCB will follow it. Preparative regimen is&#xD;
      Fludarabine 150 mg/m2/Cytoxan 50 mg/m2/Thiotepa 10 mg/m2/TBI 400cGy.&#xD;
&#xD;
      Following successful engraftment in the first cohort, second cohort (10 patients) will only&#xD;
      receive single manipulated unit.&#xD;
&#xD;
      Otherwise, patients will receive standard allogeneic stem cell transplantation care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Actual">March 10, 2021</completion_date>
  <primary_completion_date type="Actual">March 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Open label single arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Infusion Reaction</measure>
    <time_frame>42 days</time_frame>
    <description>Safety as measured by the incidence of infusion related reactions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Graft Failure</measure>
    <time_frame>42 days</time_frame>
    <description>Safety as measured by the incidence of graft failures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>1 year</time_frame>
    <description>Transplant related outcomes: time to neutrophil engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelets engraftment</measure>
    <time_frame>1 year</time_frame>
    <description>Transplant related outcomes: time to platelets engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of transplant-related mortality (TRM)</measure>
    <time_frame>1 year</time_frame>
    <description>Transplant related outcomes: transplant-related mortality (TRM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of disease free survivals</measure>
    <time_frame>1 year</time_frame>
    <description>Transplant related outcomes: Number of disease free survivals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of overall survivals</measure>
    <time_frame>1 year</time_frame>
    <description>Transplant related outcomes: Number of overall survivals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants at risk of GVHD</measure>
    <time_frame>1 year</time_frame>
    <description>Transplant Related Outcomes: risk of GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infectious complications</measure>
    <time_frame>1 year</time_frame>
    <description>Transplant Related Outcomes: incidence of infectious complications - which is any documented bacterial, viral, or fungal infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to myeloid engraftment</measure>
    <time_frame>42 days</time_frame>
    <description>Assess the kinetics of engraftment and immune reconstitution by assessing time to myeloid engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to lymphoid engraftment</measure>
    <time_frame>42 days</time_frame>
    <description>Assess the kinetics of engraftment and immune reconstitution by assessing time to lymphoid engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in T cell count</measure>
    <time_frame>Baseline and 42 days</time_frame>
    <description>Assess the kinetics of engraftment and immune reconstitution by assessing the T cell count at 42 days as compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Hematological Malignancy</condition>
  <condition>Acute Leukemia in Remission</condition>
  <condition>Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>VPA expanded cord blood stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood for patients with hematological malignancies undergoing allogeneic stem cell transplantation.&#xD;
VPA expanded cord blood stem cells in patients with hematological malignancies undergoing allogeneic stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cord blood stem cells</intervention_name>
    <description>CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood .</description>
    <arm_group_label>VPA expanded cord blood stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <description>Valproic Acid (VPA) expanded cord blood stem cells</description>
    <arm_group_label>VPA expanded cord blood stem cells</arm_group_label>
    <other_name>VPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 150 mg/m2</description>
    <arm_group_label>VPA expanded cord blood stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytoxan</intervention_name>
    <description>Cytoxan 50 mg/m2</description>
    <arm_group_label>VPA expanded cord blood stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Thiotepa 10 mg/m2</description>
    <arm_group_label>VPA expanded cord blood stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TBI</intervention_name>
    <description>TBI 400cGy</description>
    <arm_group_label>VPA expanded cord blood stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Disease criteria:&#xD;
&#xD;
        Patients with the following hematological malignancies:&#xD;
&#xD;
          -  Acute Myeloid Leukemia (AML) in complete remission (CR)&#xD;
&#xD;
          -  Acute Lymphoblastic Leukemia (ALL) in complete remission (CR)&#xD;
&#xD;
          -  Myelodysplastic Syndrome (MDS) requiring intensive chemotherapy&#xD;
&#xD;
          -  Non-Hodgkin lymphoma in complete or partial remission&#xD;
&#xD;
          -  Hodgkin lymphoma in complete or partial remission&#xD;
&#xD;
        Age Criteria:&#xD;
&#xD;
        - 18 years up to 65 years.&#xD;
&#xD;
        Organ Function and Performance Status Criteria:&#xD;
&#xD;
        - Performance status score: Karnofsky Score ≥60&#xD;
&#xD;
        Adequate major organ function defined as:&#xD;
&#xD;
          -  Left ventricular ejection fraction ≥40%&#xD;
&#xD;
          -  Pulmonary function test demonstrating DLCO ≥50% predicted and corrected for hemoglobin&#xD;
&#xD;
          -  Serum creatinine ≤ 2 mg/dL&#xD;
&#xD;
          -  Transaminases ≤ 3x ULN&#xD;
&#xD;
          -  Bilirubin ≤3x ULN except for in case of Gilbert's syndrome or ongoing hemolysis&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Donor availability:&#xD;
&#xD;
        -Lack of suitable HLA matched related or unrelated donor available within 30 days or less&#xD;
        if BMT is urgent in the opinion of the transplant physician.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Progressive, persistent disease or active malignancy&#xD;
&#xD;
          -  Greater than 10% blasts on bone marrow biopsy in patients with MDS&#xD;
&#xD;
          -  Chemotherapy naïve&#xD;
&#xD;
          -  History of myelofibrosis&#xD;
&#xD;
          -  Presence of Bone Marrow Fibrosis grade 2/3&#xD;
&#xD;
          -  Presence of donor specific anti-HLA antibodies against available UCB units at A, B, C&#xD;
             or DR loci, with a mean fluorescence intensity (MFI)&gt;1000&#xD;
&#xD;
          -  History of prior allogeneic stem cell transplantation&#xD;
&#xD;
          -  Uncontrolled viral, bacterial or fungal infection&#xD;
&#xD;
          -  History of HIV infection&#xD;
&#xD;
          -  Presence of active CNS disease at the time of transplantation&#xD;
&#xD;
          -  Pregnant or breastfeeding female&#xD;
&#xD;
          -  Inability or unwillingness to use effective birth control.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alla Keyzner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Alla Keyzner</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Hematological Malignancies</keyword>
  <keyword>Expanded Umbilical Cord</keyword>
  <keyword>Allogeneic Stem Cell Transplant</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

